RASSF1A: A promising target for the diagnosis and treatment of cancer

Publication date: Available online 23 January 2020Source: Clinica Chimica ActaAuthor(s): Yuling Bin, Yong Ding, Weisheng Xiao, Aijun LiaoAbstractThe Ras association domain family 1 isoform A (RASSF1A), a tumor suppressor, regulates several tumor-related signaling pathways and interferes with diverse cellular processes. RASSF1A is frequently demonstrated to be inactivated by hypermethylation in numerous types of solid cancers. It is also associated with lymph node metastasis, vascular invasion, and chemo-resistance. Therefore, reactivation of RASSF1A may be a viable strategy to block tumor progress and reverse drug resistance. In this review, we have summarized the clinical value of RASSF1A for screening, staging, and therapeutic management of human malignancies. We also highlighted the potential mechanism of RASSF1A in chemo-resistance, which may help identify novel drugs in the future.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research